Skip to search formSkip to main contentSkip to account menu

GSK 1120212

Known as: GSK-1120212, GSK1120212, MEK Inhibitor GSK1120212 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

trametinib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers.
2017
2017
Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease in urgent need of newer therapeutic modalities. Majority of patients… 
2016
2016
A three-part, phase I, dose-escalation study of GSK1120212, a potent MEK inhibitor, administered orally to subjects with solid tumors or lymphoma.
e14584 Background: GSK1120212 is a potent and highly selective inhibitor of MEK1, a component of the MAP kinase pathway… 
2016
2016
Calcineurin inhibitors suppress intestinal cellular respiration
The calcineurin inhibitors, tacrolimus and cyclosporine, are commonly used immunosuppressants, and transplant patients on these… 
2014
2014
Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant–Expressing Melanoma
Resistance to RAF inhibitors such as vemurafenib and dabrafenib is a major clinical problem in the treatment of melanoma… 
2012
2012
A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with…
3023 Background: Trametinib, an oral MEK1/MEK2 inhibitor, has demonstrated single-agent clinical activity. In vitro studies of… 
2012
2012
A phase I study determining the safety and tolerability of combination therapy with pazopanib, a VEGFR/PDGFR/raf inhibitor, and GSK1120212, a MEK inhibitor, in advanced solid tumors enriched with…
TPS3117 Background: Mutations of the RAS/RAF/MEK/ERK signaling pathway, especially RAS, BRAF and IGF-I/II receptor genes play a… 
Review
2011
Review
2011
Detection of novel genetic aberrations in salivary duct carcinoma (SDC) by SNaPshot analysis.
5579 Background: Salivary gland cancers (SGCs) are rare and heterogeneous malignancies, with SDC being one of the more aggressive… 
2011
2011
Abstract 3585: Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Purpose: MAPK-pathway is one of the most important… 
2010
2010
GSK1120212, a MEK1/MEK2 Inhibitor, Demonstrates Acceptable Tolerability and Preliminary Activity In a Dose Rising Trial In Subjects with AML and Other Hematologic Malignancies
Abstract 3281 Background: MEK (mitogen-activated extracellular signal-related kinase) is downstream of the RAS/RAF pathway and is… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)